[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fQ3HAjPkO5wFqoUsVYRVml8y0Si6fMUCWNArNRuKaTXs":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":71,"rows":78},"Laval University",[4],373,false,75,15,107597,7,308,[14,17,20,23,25,28,31,33],{"name":15,"count":16},"Obesity",25,{"name":18,"count":19},"Asthma",22,{"name":21,"count":22},"Metabolic Syndrome",16,{"name":24,"count":9},"Chronic Obstructive Pulmonary Disease",{"name":26,"count":27},"Insulin Resistance",9,{"name":29,"count":30},"Cardiovascular Disease",8,{"name":32,"count":30},"Overweight",{"name":34,"count":11},"Cardiovascular Diseases",[36,41,46,51,56,61,66],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT03302195","Optimal Cardiopulmonary Bypass and Anticoagulation Management Strategies in Obese Patients Undergoing Cardiac Surgery","2024-12-31","Heparin",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT05471479","Activated CHARcoal in Poisoned Patient - Pilot Trial","2026-06-01","Activated Charcoal",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT05469165","Serotonin Receptor Blockers in Ischemic Mitral Regurgitation","2026-09","Cyproheptadine 4 Mg Oral",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT04578171","Residual Exacerbations With Mepolizumab","2027-01","Mepolizumab",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT06779149","Efficacy of CBT-I and Lemborexant Medication for Different Subtypes of Chronic Insomnia","2027-02","Lemborexant",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT07409831","Incretin-based Therapies, Nutrition, and Physical Activity","2028-03","Incretin-Based Treatment",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT06620562","Improving Efficacity of Sleeve Gastrectomy With Naltrexone\u002FBupropion Extended-release Tablet","2028-06","Naltrexone\u002FBupropion",[72,73,74,75,76,77],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[79,105,127,149,185,206,229,250,288,323,349,373,399,422,447,473,498,522,540,566,584,610,628,654,672,697,722,740,763,785,810,858,884,902,928,955,973,1000,1018,1043,1061,1087,1113,1138,1159,1192,1217,1241,1264,1289,1317,1340,1370,1388,1406,1424,1442,1470,1509,1527,1550,1574,1599,1617,1641,1665,1690,1715,1739,1762,1784,1802,1827,1851],{"intervention":70,"totalTrials":80,"cells":81},1,{"EARLY_PHASE1":82,"PHASE1":85,"PHASE2":87,"PHASE3":89,"PHASE4":91,"NA":103},{"trials":83,"activeCount":84},[],0,{"trials":86,"activeCount":84},[],{"trials":88,"activeCount":84},[],{"trials":90,"activeCount":84},[],{"trials":92,"activeCount":80,"soonestReadout":69},[93],{"nctId":67,"briefTitle":68,"status":94,"phases":95,"primaryCompletion":69,"completion":96,"start":97,"enrollment":98,"conditions":99,"interventions":102},"RECRUITING",[76],"2028-08","2025-06-04",108,[100,101],"Obesity; Drug","Obesity, Morbid",[70],{"trials":104,"activeCount":84},[],{"intervention":45,"totalTrials":80,"cells":106},{"EARLY_PHASE1":107,"PHASE1":109,"PHASE2":111,"PHASE3":113,"PHASE4":115,"NA":125},{"trials":108,"activeCount":84},[],{"trials":110,"activeCount":84},[],{"trials":112,"activeCount":84},[],{"trials":114,"activeCount":84},[],{"trials":116,"activeCount":80,"soonestReadout":44},[117],{"nctId":42,"briefTitle":43,"status":94,"phases":118,"primaryCompletion":44,"completion":119,"start":120,"enrollment":121,"conditions":122,"interventions":124},[76],"2027-02-01","2025-07-16",100,[123],"Charcoal, Decontamination, Poisoning",[45],{"trials":126,"activeCount":84},[],{"intervention":50,"totalTrials":80,"cells":128},{"EARLY_PHASE1":129,"PHASE1":131,"PHASE2":133,"PHASE3":143,"PHASE4":145,"NA":147},{"trials":130,"activeCount":84},[],{"trials":132,"activeCount":84},[],{"trials":134,"activeCount":80,"soonestReadout":49},[135],{"nctId":47,"briefTitle":48,"status":94,"phases":136,"primaryCompletion":49,"completion":137,"start":138,"enrollment":139,"conditions":140,"interventions":142},[74],"2027-09","2023-06-20",214,[141],"Ischemic Mitral Regurgitation",[50],{"trials":144,"activeCount":84},[],{"trials":146,"activeCount":84},[],{"trials":148,"activeCount":84},[],{"intervention":40,"totalTrials":150,"cells":151},2,{"EARLY_PHASE1":152,"PHASE1":154,"PHASE2":156,"PHASE3":158,"PHASE4":160,"NA":175},{"trials":153,"activeCount":84},[],{"trials":155,"activeCount":84},[],{"trials":157,"activeCount":84},[],{"trials":159,"activeCount":84},[],{"trials":161,"activeCount":84},[162],{"nctId":163,"briefTitle":164,"status":165,"phases":166,"primaryCompletion":167,"completion":168,"start":169,"enrollment":170,"conditions":171,"interventions":173},"NCT01084993","EArly Discharge After Transradial Stenting of CoronarY Arteries in High-Risk Patients of Bleeding","UNKNOWN",[76],"2018-09","2019-01","2010-03",2000,[172],"Coronary Artery Disease",[174,40],"Bivalirudin",{"trials":176,"activeCount":80,"soonestReadout":39},[177],{"nctId":37,"briefTitle":38,"status":94,"phases":178,"primaryCompletion":39,"completion":179,"start":180,"enrollment":181,"conditions":182,"interventions":184},[77],"2027-12-31","2015-08-21",410,[183,15],"Cardiopulmonary Bypass",[40],{"intervention":60,"totalTrials":80,"cells":186},{"EARLY_PHASE1":187,"PHASE1":189,"PHASE2":191,"PHASE3":193,"PHASE4":195,"NA":197},{"trials":188,"activeCount":84},[],{"trials":190,"activeCount":84},[],{"trials":192,"activeCount":84},[],{"trials":194,"activeCount":84},[],{"trials":196,"activeCount":84},[],{"trials":198,"activeCount":80,"soonestReadout":59},[199],{"nctId":57,"briefTitle":58,"status":94,"phases":200,"primaryCompletion":59,"completion":59,"start":201,"enrollment":202,"conditions":203,"interventions":205},[77],"2025-04-01",90,[204],"Insomnia Disorder",[60],{"intervention":65,"totalTrials":80,"cells":207},{"EARLY_PHASE1":208,"PHASE1":210,"PHASE2":212,"PHASE3":214,"PHASE4":216,"NA":218},{"trials":209,"activeCount":84},[],{"trials":211,"activeCount":84},[],{"trials":213,"activeCount":84},[],{"trials":215,"activeCount":84},[],{"trials":217,"activeCount":84},[],{"trials":219,"activeCount":80,"soonestReadout":64},[220],{"nctId":62,"briefTitle":63,"status":221,"phases":222,"primaryCompletion":64,"completion":64,"start":223,"enrollment":224,"conditions":225,"interventions":228},"NOT_YET_RECRUITING",[77],"2026-03",120,[226,227],"Obesity & Overweight","Cardiometabolic Conditions",[65],{"intervention":55,"totalTrials":80,"cells":230},{"EARLY_PHASE1":231,"PHASE1":233,"PHASE2":235,"PHASE3":237,"PHASE4":239,"NA":241},{"trials":232,"activeCount":84},[],{"trials":234,"activeCount":84},[],{"trials":236,"activeCount":84},[],{"trials":238,"activeCount":84},[],{"trials":240,"activeCount":84},[],{"trials":242,"activeCount":80,"soonestReadout":54},[243],{"nctId":52,"briefTitle":53,"status":94,"phases":244,"primaryCompletion":54,"completion":245,"start":246,"enrollment":247,"conditions":248,"interventions":249},[],"2028-01","2021-07-06",60,[18],[55],{"intervention":251,"totalTrials":150,"cells":252},"Methylphenidate",{"EARLY_PHASE1":253,"PHASE1":255,"PHASE2":257,"PHASE3":259,"PHASE4":273,"NA":286},{"trials":254,"activeCount":84},[],{"trials":256,"activeCount":84},[],{"trials":258,"activeCount":84},[],{"trials":260,"activeCount":84},[261],{"nctId":262,"briefTitle":263,"status":264,"phases":265,"primaryCompletion":266,"completion":267,"start":268,"enrollment":269,"conditions":270,"interventions":272},"NCT01421992","Methylphenidate in Myotonic Dystrophy Type 1","COMPLETED",[74,75],"2010-08","2010-09","2008-06",28,[271],"Dystrophia Myotonica 1",[251],{"trials":274,"activeCount":84},[275],{"nctId":276,"briefTitle":277,"status":278,"phases":279,"primaryCompletion":280,"completion":280,"start":281,"enrollment":282,"conditions":283,"interventions":285},"NCT01244269","The Effect of Methylphenidate on Non-motor Symptoms and Postural Control in Parkinson's Disease.","TERMINATED",[76],"2011-06","2010-12",6,[284],"Parkinson's Disease",[251,251],{"trials":287,"activeCount":84},[],{"intervention":289,"totalTrials":150,"cells":290},"Abciximab",{"EARLY_PHASE1":291,"PHASE1":293,"PHASE2":295,"PHASE3":297,"PHASE4":299,"NA":321},{"trials":292,"activeCount":84},[],{"trials":294,"activeCount":84},[],{"trials":296,"activeCount":84},[],{"trials":298,"activeCount":84},[],{"trials":300,"activeCount":84},[301,311],{"nctId":302,"briefTitle":303,"status":264,"phases":304,"completion":305,"start":306,"enrollment":307,"conditions":308,"interventions":310},"NCT00169819","EArly Discharge After Transradial Stenting of CoronarY Arteries: The EASY Study",[76],"2006-04","2003-10",1000,[172,309],"Ischemia",[289],{"nctId":312,"briefTitle":313,"status":264,"phases":314,"primaryCompletion":315,"completion":315,"start":316,"enrollment":317,"conditions":318,"interventions":320},"NCT00440778","A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI",[76],"2008-10","2007-02",105,[319,309],"Myocardial Infarction",[289],{"trials":322,"activeCount":84},[],{"intervention":324,"totalTrials":80,"cells":325},"Capsimax",{"EARLY_PHASE1":326,"PHASE1":328,"PHASE2":330,"PHASE3":332,"PHASE4":334,"NA":347},{"trials":327,"activeCount":84},[],{"trials":329,"activeCount":84},[],{"trials":331,"activeCount":84},[],{"trials":333,"activeCount":84},[],{"trials":335,"activeCount":84},[336],{"nctId":337,"briefTitle":338,"status":264,"phases":339,"primaryCompletion":340,"completion":340,"start":341,"enrollment":342,"conditions":343,"interventions":346},"NCT04874701","Effects of Capsimax on Appetite, Energy Intake and Blood Pressure",[76],"2019-07-02","2018-01-07",63,[15,344,345,32],"Body Weight","Weight Loss",[324],{"trials":348,"activeCount":84},[],{"intervention":350,"totalTrials":80,"cells":351},"Caltrate® 600 + D",{"EARLY_PHASE1":352,"PHASE1":354,"PHASE2":356,"PHASE3":358,"PHASE4":360,"NA":371},{"trials":353,"activeCount":84},[],{"trials":355,"activeCount":84},[],{"trials":357,"activeCount":84},[],{"trials":359,"activeCount":84},[],{"trials":361,"activeCount":84},[362],{"nctId":363,"briefTitle":364,"status":264,"phases":365,"completion":366,"start":367,"enrollment":368,"conditions":369,"interventions":370},"NCT00353054","Effect of Calcium\u002FVitamin D Supplementation on Body Weight and Fat Loss.",[76],"2005-07","2003-01",80,[15,32],[350],{"trials":372,"activeCount":84},[],{"intervention":374,"totalTrials":80,"cells":375},"Sibutramine",{"EARLY_PHASE1":376,"PHASE1":378,"PHASE2":380,"PHASE3":382,"PHASE4":384,"NA":397},{"trials":377,"activeCount":84},[],{"trials":379,"activeCount":84},[],{"trials":381,"activeCount":84},[],{"trials":383,"activeCount":84},[],{"trials":385,"activeCount":84},[386],{"nctId":387,"briefTitle":388,"status":264,"phases":389,"primaryCompletion":390,"completion":390,"start":391,"enrollment":392,"conditions":393,"interventions":396},"NCT00729963","Sibutramine Versus Continuous Positive Airway Pressure (CPAP)in Obstructive Sleep Apnea (OSA) Patients",[76],"2007-09","2004-01",45,[394,15,395],"Obstructive Sleep Apnea","Hypertension",[374],{"trials":398,"activeCount":84},[],{"intervention":400,"totalTrials":80,"cells":401},"Tiotropium",{"EARLY_PHASE1":402,"PHASE1":404,"PHASE2":406,"PHASE3":408,"PHASE4":410,"NA":420},{"trials":403,"activeCount":84},[],{"trials":405,"activeCount":84},[],{"trials":407,"activeCount":84},[],{"trials":409,"activeCount":84},[],{"trials":411,"activeCount":84},[412],{"nctId":413,"briefTitle":414,"status":264,"phases":415,"completion":266,"start":416,"enrollment":417,"conditions":418,"interventions":419},"NCT01307189","Effects of Tiotropium on Walking Capacity in Patients With COPD",[76],"2005-04",33,[24],[400],{"trials":421,"activeCount":84},[],{"intervention":423,"totalTrials":80,"cells":424},"Clopidogrel",{"EARLY_PHASE1":425,"PHASE1":427,"PHASE2":429,"PHASE3":431,"PHASE4":433,"NA":445},{"trials":426,"activeCount":84},[],{"trials":428,"activeCount":84},[],{"trials":430,"activeCount":84},[],{"trials":432,"activeCount":84},[],{"trials":434,"activeCount":84},[435],{"nctId":436,"briefTitle":437,"status":264,"phases":438,"primaryCompletion":439,"completion":440,"start":315,"enrollment":441,"conditions":442,"interventions":444},"NCT00799045","Clopidogrel For the Prevention of New Onset Migraine Headache Following Transcatheter Closure of Atrial Septal Defects",[76],"2015-04","2016-12",220,[443],"Migraine",[423],{"trials":446,"activeCount":84},[],{"intervention":448,"totalTrials":80,"cells":449},"Carbetocin",{"EARLY_PHASE1":450,"PHASE1":452,"PHASE2":454,"PHASE3":456,"PHASE4":458,"NA":471},{"trials":451,"activeCount":84},[],{"trials":453,"activeCount":84},[],{"trials":455,"activeCount":84},[],{"trials":457,"activeCount":84},[],{"trials":459,"activeCount":84},[460],{"nctId":461,"briefTitle":462,"status":264,"phases":463,"primaryCompletion":464,"completion":464,"start":465,"enrollment":466,"conditions":467,"interventions":470},"NCT01630187","Comparison of Two Doses of Carbetocin for Prevention of Uterine Atony, During Elective Cesarean Section",[76],"2012-07","2012-04",72,[468,469],"Uterine Atony","Post-partum Hemorrhage",[448,448],{"trials":472,"activeCount":84},[],{"intervention":474,"totalTrials":80,"cells":475},"Cinacalcet",{"EARLY_PHASE1":476,"PHASE1":478,"PHASE2":480,"PHASE3":482,"PHASE4":484,"NA":496},{"trials":477,"activeCount":84},[],{"trials":479,"activeCount":84},[],{"trials":481,"activeCount":84},[],{"trials":483,"activeCount":84},[],{"trials":485,"activeCount":84},[486],{"nctId":487,"briefTitle":488,"status":264,"phases":489,"primaryCompletion":490,"completion":490,"start":491,"enrollment":492,"conditions":493,"interventions":495},"NCT01250405","Acute Effects of Cinacalcet on Arterial Stiffness and Ventricular Function in Hemodialysis Patients",[76],"2014-04","2012-05",23,[494],"Chronic Kidney Disease",[474],{"trials":497,"activeCount":84},[],{"intervention":499,"totalTrials":80,"cells":500},"zolpidem",{"EARLY_PHASE1":501,"PHASE1":503,"PHASE2":505,"PHASE3":507,"PHASE4":509,"NA":520},{"trials":502,"activeCount":84},[],{"trials":504,"activeCount":84},[],{"trials":506,"activeCount":84},[],{"trials":508,"activeCount":84},[],{"trials":510,"activeCount":84},[511],{"nctId":512,"briefTitle":513,"status":264,"phases":514,"start":515,"enrollment":516,"conditions":517,"interventions":519},"NCT00042146","Behavioral and Pharmacological Treatment for Insomnia",[76],"2001-12",160,[518],"Sleep Initiation and Maintenance Disorders",[499],{"trials":521,"activeCount":84},[],{"intervention":174,"totalTrials":80,"cells":523},{"EARLY_PHASE1":524,"PHASE1":526,"PHASE2":528,"PHASE3":530,"PHASE4":532,"NA":538},{"trials":525,"activeCount":84},[],{"trials":527,"activeCount":84},[],{"trials":529,"activeCount":84},[],{"trials":531,"activeCount":84},[],{"trials":533,"activeCount":84},[534],{"nctId":163,"briefTitle":164,"status":165,"phases":535,"primaryCompletion":167,"completion":168,"start":169,"enrollment":170,"conditions":536,"interventions":537},[76],[172],[174,40],{"trials":539,"activeCount":84},[],{"intervention":541,"totalTrials":80,"cells":542},"Ultibro®",{"EARLY_PHASE1":543,"PHASE1":545,"PHASE2":547,"PHASE3":549,"PHASE4":551,"NA":564},{"trials":544,"activeCount":84},[],{"trials":546,"activeCount":84},[],{"trials":548,"activeCount":84},[],{"trials":550,"activeCount":84},[],{"trials":552,"activeCount":84},[553],{"nctId":554,"briefTitle":555,"status":264,"phases":556,"primaryCompletion":557,"completion":557,"start":558,"enrollment":559,"conditions":560,"interventions":562},"NCT02567214","Ultibro® Versus Spiriva® Alone to Reduce Exertional Dyspnea in Patients With Moderate to Severe COPD",[76],"2018-11-30","2016-06",50,[561],"COPD",[541,563],"Spiriva®",{"trials":565,"activeCount":84},[],{"intervention":563,"totalTrials":80,"cells":567},{"EARLY_PHASE1":568,"PHASE1":570,"PHASE2":572,"PHASE3":574,"PHASE4":576,"NA":582},{"trials":569,"activeCount":84},[],{"trials":571,"activeCount":84},[],{"trials":573,"activeCount":84},[],{"trials":575,"activeCount":84},[],{"trials":577,"activeCount":84},[578],{"nctId":554,"briefTitle":555,"status":264,"phases":579,"primaryCompletion":557,"completion":557,"start":558,"enrollment":559,"conditions":580,"interventions":581},[76],[561],[541,563],{"trials":583,"activeCount":84},[],{"intervention":585,"totalTrials":80,"cells":586},"Infanrix-hexa",{"EARLY_PHASE1":587,"PHASE1":589,"PHASE2":591,"PHASE3":593,"PHASE4":595,"NA":608},{"trials":588,"activeCount":84},[],{"trials":590,"activeCount":84},[],{"trials":592,"activeCount":84},[],{"trials":594,"activeCount":84},[],{"trials":596,"activeCount":84},[597],{"nctId":598,"briefTitle":599,"status":264,"phases":600,"primaryCompletion":601,"completion":601,"start":602,"enrollment":603,"conditions":604,"interventions":606},"NCT04294433","Immunogenicity of 2 Versus 3 Doses of Combined Hepatitis B Vaccines in 2-18 Months Old Children",[76],"2023-12-30","2018-06-11",431,[605],"Hepatitis B",[585,607],"Infanrix-hexa and Twinrix Junior",{"trials":609,"activeCount":84},[],{"intervention":607,"totalTrials":80,"cells":611},{"EARLY_PHASE1":612,"PHASE1":614,"PHASE2":616,"PHASE3":618,"PHASE4":620,"NA":626},{"trials":613,"activeCount":84},[],{"trials":615,"activeCount":84},[],{"trials":617,"activeCount":84},[],{"trials":619,"activeCount":84},[],{"trials":621,"activeCount":84},[622],{"nctId":598,"briefTitle":599,"status":264,"phases":623,"primaryCompletion":601,"completion":601,"start":602,"enrollment":603,"conditions":624,"interventions":625},[76],[605],[585,607],{"trials":627,"activeCount":84},[],{"intervention":629,"totalTrials":80,"cells":630},"Hyaluronan",{"EARLY_PHASE1":631,"PHASE1":633,"PHASE2":635,"PHASE3":637,"PHASE4":639,"NA":652},{"trials":632,"activeCount":84},[],{"trials":634,"activeCount":84},[],{"trials":636,"activeCount":84},[],{"trials":638,"activeCount":84},[],{"trials":640,"activeCount":84},[641],{"nctId":642,"briefTitle":643,"status":264,"phases":644,"primaryCompletion":645,"completion":645,"start":646,"enrollment":647,"conditions":648,"interventions":650},"NCT02086474","Daily Activity and Gait Analysis After Viscosupplement Injection Among Hip Osteoarthritis Patients",[76],"2017-08","2014-05",38,[649],"Hip Osteoarthritis",[629,651],"Bupivacaine",{"trials":653,"activeCount":84},[],{"intervention":651,"totalTrials":80,"cells":655},{"EARLY_PHASE1":656,"PHASE1":658,"PHASE2":660,"PHASE3":662,"PHASE4":664,"NA":670},{"trials":657,"activeCount":84},[],{"trials":659,"activeCount":84},[],{"trials":661,"activeCount":84},[],{"trials":663,"activeCount":84},[],{"trials":665,"activeCount":84},[666],{"nctId":642,"briefTitle":643,"status":264,"phases":667,"primaryCompletion":645,"completion":645,"start":646,"enrollment":647,"conditions":668,"interventions":669},[76],[649],[629,651],{"trials":671,"activeCount":84},[],{"intervention":673,"totalTrials":80,"cells":674},"Engerix-B",{"EARLY_PHASE1":675,"PHASE1":677,"PHASE2":679,"PHASE3":681,"PHASE4":683,"NA":695},{"trials":676,"activeCount":84},[],{"trials":678,"activeCount":84},[],{"trials":680,"activeCount":84},[],{"trials":682,"activeCount":84},[],{"trials":684,"activeCount":84},[685],{"nctId":686,"briefTitle":687,"status":264,"phases":688,"primaryCompletion":689,"completion":491,"start":690,"enrollment":691,"conditions":692,"interventions":694},"NCT00169858","Long Term Immunogenicity Study of Engerix-B Vaccine in 10 Year Old Children and the Effect of Booster Injections",[76],"2011-10","1995-09",1129,[605,693],"Vaccination",[673],{"trials":696,"activeCount":84},[],{"intervention":698,"totalTrials":80,"cells":699},"Dexamethasone IV",{"EARLY_PHASE1":700,"PHASE1":702,"PHASE2":704,"PHASE3":706,"PHASE4":708,"NA":720},{"trials":701,"activeCount":84},[],{"trials":703,"activeCount":84},[],{"trials":705,"activeCount":84},[],{"trials":707,"activeCount":84},[],{"trials":709,"activeCount":84},[710],{"nctId":711,"briefTitle":712,"status":264,"phases":713,"primaryCompletion":714,"completion":440,"start":715,"enrollment":121,"conditions":716,"interventions":718},"NCT02275702","Randomized Study of Preoperative Dexamethasone for Quality of Recovery in VATS Lung Resection Patients",[76],"2016-10","2014-10",[717],"Lung Cancer",[698,719],"Saline solution",{"trials":721,"activeCount":84},[],{"intervention":719,"totalTrials":80,"cells":723},{"EARLY_PHASE1":724,"PHASE1":726,"PHASE2":728,"PHASE3":730,"PHASE4":732,"NA":738},{"trials":725,"activeCount":84},[],{"trials":727,"activeCount":84},[],{"trials":729,"activeCount":84},[],{"trials":731,"activeCount":84},[],{"trials":733,"activeCount":84},[734],{"nctId":711,"briefTitle":712,"status":264,"phases":735,"primaryCompletion":714,"completion":440,"start":715,"enrollment":121,"conditions":736,"interventions":737},[76],[717],[698,719],{"trials":739,"activeCount":84},[],{"intervention":741,"totalTrials":80,"cells":742},"Salmeterol diskus inhalation powder",{"EARLY_PHASE1":743,"PHASE1":745,"PHASE2":747,"PHASE3":749,"PHASE4":751,"NA":761},{"trials":744,"activeCount":84},[],{"trials":746,"activeCount":84},[],{"trials":748,"activeCount":84},[],{"trials":750,"activeCount":84},[],{"trials":752,"activeCount":84},[753],{"nctId":754,"briefTitle":755,"status":264,"phases":756,"completion":757,"start":758,"enrollment":269,"conditions":759,"interventions":760},"NCT00525564","Effects of Salmeterol on Walking Capacity in Patients With COPD",[76],"2006-10","2006-05",[24],[741],{"trials":762,"activeCount":84},[],{"intervention":764,"totalTrials":80,"cells":765},"Atorvastatin",{"EARLY_PHASE1":766,"PHASE1":768,"PHASE2":770,"PHASE3":772,"PHASE4":774,"NA":783},{"trials":767,"activeCount":84},[],{"trials":769,"activeCount":84},[],{"trials":771,"activeCount":84},[],{"trials":773,"activeCount":84},[],{"trials":775,"activeCount":84},[776],{"nctId":777,"briefTitle":778,"status":264,"phases":779,"primaryCompletion":646,"completion":780,"start":315,"enrollment":492,"conditions":781,"interventions":782},"NCT00768638","Study of Atorvastatin Dose Dependent Reduction of Proteinuria",[76],"2014-06",[494],[764,764],{"trials":784,"activeCount":84},[],{"intervention":786,"totalTrials":80,"cells":787},"Corticosteroids",{"EARLY_PHASE1":788,"PHASE1":790,"PHASE2":792,"PHASE3":794,"PHASE4":796,"NA":808},{"trials":789,"activeCount":84},[],{"trials":791,"activeCount":84},[],{"trials":793,"activeCount":84},[],{"trials":795,"activeCount":84},[],{"trials":797,"activeCount":84},[798],{"nctId":799,"briefTitle":800,"status":264,"phases":801,"primaryCompletion":802,"completion":802,"start":803,"enrollment":804,"conditions":805,"interventions":807},"NCT02049879","Daily Activity After Corticosteroids Injection Among Knee Osteoarthritis Patients",[76],"2012-08","2008-11",14,[806],"Knee Osteoarthritis",[786],{"trials":809,"activeCount":84},[],{"intervention":811,"totalTrials":812,"cells":813},"Sitagliptin",3,{"EARLY_PHASE1":814,"PHASE1":816,"PHASE2":818,"PHASE3":820,"PHASE4":854,"NA":856},{"trials":815,"activeCount":84},[],{"trials":817,"activeCount":84},[],{"trials":819,"activeCount":84},[],{"trials":821,"activeCount":84},[822,833,845],{"nctId":823,"briefTitle":824,"status":264,"phases":825,"primaryCompletion":826,"completion":827,"start":828,"enrollment":829,"conditions":830,"interventions":832},"NCT02536248","Sitagliptin Therapy and Kinetics of Inflammatory Markers",[75],"2017-09-30","2017-10-31","2015-08-01",20,[831],"Type 2 Diabetes Mellitus",[811],{"nctId":834,"briefTitle":835,"status":264,"phases":836,"primaryCompletion":837,"completion":838,"start":839,"enrollment":840,"conditions":841,"interventions":844},"NCT00660075","Effects of Sitagliptin on Postprandial Lipemia in Men With Type 2 Diabetes",[75],"2009-01","2009-04","2008-02",36,[842,843],"Diabetes Mellitus","Postprandial Lipemia",[811],{"nctId":846,"briefTitle":847,"status":264,"phases":848,"primaryCompletion":849,"completion":850,"start":851,"enrollment":19,"conditions":852,"interventions":853},"NCT01334229","Sitagliptin and Kinetics of Triglyceride-rich Lipoproteins Apolipoprotein B48 and B100 in Patients With Type 2 Diabetes",[75],"2013-03","2013-12","2011-04",[831],[811],{"trials":855,"activeCount":84},[],{"trials":857,"activeCount":84},[],{"intervention":859,"totalTrials":80,"cells":860},"Gardasil vaccine, Immunogenicity, Booster dose.",{"EARLY_PHASE1":861,"PHASE1":863,"PHASE2":865,"PHASE3":867,"PHASE4":880,"NA":882},{"trials":862,"activeCount":84},[],{"trials":864,"activeCount":84},[],{"trials":866,"activeCount":84},[],{"trials":868,"activeCount":84},[869],{"nctId":870,"briefTitle":871,"status":264,"phases":872,"primaryCompletion":873,"completion":873,"start":874,"enrollment":875,"conditions":876,"interventions":878},"NCT01456715","Immunogenicity of Gardasil and Twinrix and the Effect of a Dose of Gardasil or Cervarix Given 42 Months Later.",[75],"2018-12","2008-09",418,[877],"Human Papillomavirus",[859,879],"Cervarix Vaccine, Immunogenicity, Booster Dose.",{"trials":881,"activeCount":84},[],{"trials":883,"activeCount":84},[],{"intervention":879,"totalTrials":80,"cells":885},{"EARLY_PHASE1":886,"PHASE1":888,"PHASE2":890,"PHASE3":892,"PHASE4":898,"NA":900},{"trials":887,"activeCount":84},[],{"trials":889,"activeCount":84},[],{"trials":891,"activeCount":84},[],{"trials":893,"activeCount":84},[894],{"nctId":870,"briefTitle":871,"status":264,"phases":895,"primaryCompletion":873,"completion":873,"start":874,"enrollment":875,"conditions":896,"interventions":897},[75],[877],[859,879],{"trials":899,"activeCount":84},[],{"trials":901,"activeCount":84},[],{"intervention":903,"totalTrials":80,"cells":904},"Duavive",{"EARLY_PHASE1":905,"PHASE1":907,"PHASE2":909,"PHASE3":911,"PHASE4":924,"NA":926},{"trials":906,"activeCount":84},[],{"trials":908,"activeCount":84},[],{"trials":910,"activeCount":84},[],{"trials":912,"activeCount":84},[913],{"nctId":914,"briefTitle":915,"status":165,"phases":916,"primaryCompletion":917,"completion":917,"start":918,"enrollment":840,"conditions":919,"interventions":923},"NCT03981341","Impact of Estrogen + Estradiol Receptor Alpha Modulator Therapy on Oxidative Stress in Post-menopausal Women With and Without Sleep Apnea",[75],"2023-12-01","2019-11-01",[920,921,922],"Sleep Apnea","Post Menopausal","Oxidative Stress",[903],{"trials":925,"activeCount":84},[],{"trials":927,"activeCount":84},[],{"intervention":929,"totalTrials":80,"cells":930},"Ondansetron 4 MG",{"EARLY_PHASE1":931,"PHASE1":933,"PHASE2":935,"PHASE3":937,"PHASE4":951,"NA":953},{"trials":932,"activeCount":84},[],{"trials":934,"activeCount":84},[],{"trials":936,"activeCount":84},[],{"trials":938,"activeCount":84},[939],{"nctId":940,"briefTitle":941,"status":165,"phases":942,"primaryCompletion":943,"completion":943,"start":944,"enrollment":247,"conditions":945,"interventions":949},"NCT04703088","ONDANSETRON AND EFFECTIVE DOSE IN 50% OF SUBJECTS OF PROPHYLACTIC NOREPINEPHRINE INFUSIONS FOR PREVENTING SPINAL ANESTHESIA-INDUCED HYPOTENSION DURING CESAREAN DELIVERY",[75],"2021-08","2021-06",[946,947,948],"Hypotension","Anesthesia; Adverse Effect, Spinal and Epidural","Cesarean Section",[929,950],"0.9% Saline",{"trials":952,"activeCount":84},[],{"trials":954,"activeCount":84},[],{"intervention":950,"totalTrials":80,"cells":956},{"EARLY_PHASE1":957,"PHASE1":959,"PHASE2":961,"PHASE3":963,"PHASE4":969,"NA":971},{"trials":958,"activeCount":84},[],{"trials":960,"activeCount":84},[],{"trials":962,"activeCount":84},[],{"trials":964,"activeCount":84},[965],{"nctId":940,"briefTitle":941,"status":165,"phases":966,"primaryCompletion":943,"completion":943,"start":944,"enrollment":247,"conditions":967,"interventions":968},[75],[946,947,948],[929,950],{"trials":970,"activeCount":84},[],{"trials":972,"activeCount":84},[],{"intervention":974,"totalTrials":80,"cells":975},"Immunogenicity two doses of Gardasil-9",{"EARLY_PHASE1":976,"PHASE1":978,"PHASE2":980,"PHASE3":982,"PHASE4":996,"NA":998},{"trials":977,"activeCount":84},[],{"trials":979,"activeCount":84},[],{"trials":981,"activeCount":84},[],{"trials":983,"activeCount":84},[984],{"nctId":985,"briefTitle":986,"status":264,"phases":987,"primaryCompletion":988,"completion":989,"start":990,"enrollment":991,"conditions":992,"interventions":994},"NCT02567955","Immunogenicity and Safety of Gardasil-9 and Cervarix",[75],"2016-09","2017-11","2015-09",376,[993],"HPV Vaccines Immunogenicity and Safety",[974,995],"Immunogenicity Cervarix and Gardasil-9",{"trials":997,"activeCount":84},[],{"trials":999,"activeCount":84},[],{"intervention":995,"totalTrials":80,"cells":1001},{"EARLY_PHASE1":1002,"PHASE1":1004,"PHASE2":1006,"PHASE3":1008,"PHASE4":1014,"NA":1016},{"trials":1003,"activeCount":84},[],{"trials":1005,"activeCount":84},[],{"trials":1007,"activeCount":84},[],{"trials":1009,"activeCount":84},[1010],{"nctId":985,"briefTitle":986,"status":264,"phases":1011,"primaryCompletion":988,"completion":989,"start":990,"enrollment":991,"conditions":1012,"interventions":1013},[75],[993],[974,995],{"trials":1015,"activeCount":84},[],{"trials":1017,"activeCount":84},[],{"intervention":1019,"totalTrials":80,"cells":1020},"prednisone group",{"EARLY_PHASE1":1021,"PHASE1":1023,"PHASE2":1025,"PHASE3":1027,"PHASE4":1039,"NA":1041},{"trials":1022,"activeCount":84},[],{"trials":1024,"activeCount":84},[],{"trials":1026,"activeCount":84},[],{"trials":1028,"activeCount":84},[1029],{"nctId":1030,"briefTitle":1031,"status":264,"phases":1032,"primaryCompletion":1033,"completion":1033,"start":1034,"enrollment":804,"conditions":1035,"interventions":1037},"NCT00531791","Effects of Advair® in Outpatients With Chronic Obstructive Pulmonary Disease (COPD) Acute Exacerbation",[75],"2009-09","2007-11",[1036],"Chronic Obstructive Pulmonary Disease (COPD)",[1019,1038],"Advair group",{"trials":1040,"activeCount":84},[],{"trials":1042,"activeCount":84},[],{"intervention":1038,"totalTrials":80,"cells":1044},{"EARLY_PHASE1":1045,"PHASE1":1047,"PHASE2":1049,"PHASE3":1051,"PHASE4":1057,"NA":1059},{"trials":1046,"activeCount":84},[],{"trials":1048,"activeCount":84},[],{"trials":1050,"activeCount":84},[],{"trials":1052,"activeCount":84},[1053],{"nctId":1030,"briefTitle":1031,"status":264,"phases":1054,"primaryCompletion":1033,"completion":1033,"start":1034,"enrollment":804,"conditions":1055,"interventions":1056},[75],[1036],[1019,1038],{"trials":1058,"activeCount":84},[],{"trials":1060,"activeCount":84},[],{"intervention":1062,"totalTrials":80,"cells":1063},"Rosiglitazone or placebo",{"EARLY_PHASE1":1064,"PHASE1":1066,"PHASE2":1068,"PHASE3":1070,"PHASE4":1083,"NA":1085},{"trials":1065,"activeCount":84},[],{"trials":1067,"activeCount":84},[],{"trials":1069,"activeCount":84},[],{"trials":1071,"activeCount":84},[1072],{"nctId":1073,"briefTitle":1074,"status":264,"phases":1075,"primaryCompletion":1076,"completion":1076,"start":1077,"enrollment":1078,"conditions":1079,"interventions":1082},"NCT00169832","Vein-Coronary Atherosclerosis And Rosiglitazone After Bypass Surgery: The VICTORY Trial",[75],"2007-07","2003-06",193,[1080,1081],"Diabetes","Coronary Artery Bypass Grafting",[1062],{"trials":1084,"activeCount":84},[],{"trials":1086,"activeCount":84},[],{"intervention":1088,"totalTrials":80,"cells":1089},"Gardasil and Gardasil-9",{"EARLY_PHASE1":1090,"PHASE1":1092,"PHASE2":1094,"PHASE3":1096,"PHASE4":1109,"NA":1111},{"trials":1091,"activeCount":84},[],{"trials":1093,"activeCount":84},[],{"trials":1095,"activeCount":84},[],{"trials":1097,"activeCount":84},[1098],{"nctId":1099,"briefTitle":1100,"status":264,"phases":1101,"primaryCompletion":1102,"completion":1103,"start":1104,"enrollment":1105,"conditions":1106,"interventions":1108},"NCT03431246","Immunogenicity of One Dose of Gardasil and One Dose of Gardasil-9",[75],"2016-11-05","2016-12-05","2016-10-01",32,[1107],"Human Papillomavirus Vaccines",[1088],{"trials":1110,"activeCount":84},[],{"trials":1112,"activeCount":84},[],{"intervention":1114,"totalTrials":80,"cells":1115},"Ezetimibe",{"EARLY_PHASE1":1116,"PHASE1":1118,"PHASE2":1120,"PHASE3":1122,"PHASE4":1134,"NA":1136},{"trials":1117,"activeCount":84},[],{"trials":1119,"activeCount":84},[],{"trials":1121,"activeCount":84},[],{"trials":1123,"activeCount":84},[1124],{"nctId":1125,"briefTitle":1126,"status":264,"phases":1127,"primaryCompletion":1128,"completion":1129,"start":1130,"enrollment":829,"conditions":1131,"interventions":1133},"NCT01849068","Effects of Selective Inhibition of Cholesterol Absorption With Ezetimibe on Intestinal Cholesterol Homeostasis in Dyslipidemic Men With Insulin-resistance - a Pilot Study",[75],"2015-06","2016-02","2013-06",[1132],"Metabolic Syndrome X",[1114],{"trials":1135,"activeCount":84},[],{"trials":1137,"activeCount":84},[],{"intervention":1139,"totalTrials":80,"cells":1140},"budesonide and budesonide\u002Fformoterol",{"EARLY_PHASE1":1141,"PHASE1":1143,"PHASE2":1145,"PHASE3":1147,"PHASE4":1155,"NA":1157},{"trials":1142,"activeCount":84},[],{"trials":1144,"activeCount":84},[],{"trials":1146,"activeCount":84},[],{"trials":1148,"activeCount":84},[1149],{"nctId":1150,"briefTitle":1151,"status":264,"phases":1152,"conditions":1153,"interventions":1154},"NCT00691951","Effects of Budesonide & Budesonide\u002FFormoterol on Smoking Asthmatic Subjects",[75],[18],[1139],{"trials":1156,"activeCount":84},[],{"trials":1158,"activeCount":84},[],{"intervention":1160,"totalTrials":150,"cells":1161},"Olaparib",{"EARLY_PHASE1":1162,"PHASE1":1173,"PHASE2":1175,"PHASE3":1186,"PHASE4":1188,"NA":1190},{"trials":1163,"activeCount":84},[1164],{"nctId":1165,"briefTitle":1166,"status":278,"phases":1167,"primaryCompletion":1168,"completion":1168,"start":1169,"enrollment":282,"conditions":1170,"interventions":1172},"NCT03251872","Olaparib for PAH: a Pilot Study",[72],"2019-12-01","2018-10-25",[1171],"Pulmonary Arterial Hypertension",[1160],{"trials":1174,"activeCount":84},[],{"trials":1176,"activeCount":84},[1177],{"nctId":1178,"briefTitle":1179,"status":278,"phases":1180,"primaryCompletion":1181,"completion":1181,"start":1182,"enrollment":1183,"conditions":1184,"interventions":1185},"NCT03782818","Olaparib for PAH: a Multicenter Clinical Trial",[73,74],"2024-10-31","2019-11-20",17,[1171],[1160],{"trials":1187,"activeCount":84},[],{"trials":1189,"activeCount":84},[],{"trials":1191,"activeCount":84},[],{"intervention":1193,"totalTrials":80,"cells":1194},"Invisible Condom®",{"EARLY_PHASE1":1195,"PHASE1":1197,"PHASE2":1199,"PHASE3":1211,"PHASE4":1213,"NA":1215},{"trials":1196,"activeCount":84},[],{"trials":1198,"activeCount":84},[],{"trials":1200,"activeCount":84},[1201],{"nctId":1202,"briefTitle":1203,"status":264,"phases":1204,"completion":1076,"start":1205,"enrollment":1206,"conditions":1207,"interventions":1210},"NCT00136643","Safety, Tolerance and Acceptability Trial of the Invisible Condom® in Healthy Women",[73,74],"2005-06",452,[1208,1209],"HIV Infections","Sexually Transmitted Diseases",[1193],{"trials":1212,"activeCount":84},[],{"trials":1214,"activeCount":84},[],{"trials":1216,"activeCount":84},[],{"intervention":1218,"totalTrials":80,"cells":1219},"modafinil",{"EARLY_PHASE1":1220,"PHASE1":1222,"PHASE2":1224,"PHASE3":1235,"PHASE4":1237,"NA":1239},{"trials":1221,"activeCount":84},[],{"trials":1223,"activeCount":84},[],{"trials":1225,"activeCount":84},[1226],{"nctId":1227,"briefTitle":1228,"status":264,"phases":1229,"primaryCompletion":268,"start":1230,"enrollment":1231,"conditions":1232,"interventions":1234},"NCT00314639","Modafinil as an Adjunctive on Cognitive Functioning in Patients With Schizophrenia",[73,74],"2005-09",30,[1233],"Schizophrenia and Schizophrenia Spectrum Psychosis",[1218],{"trials":1236,"activeCount":84},[],{"trials":1238,"activeCount":84},[],{"trials":1240,"activeCount":84},[],{"intervention":1242,"totalTrials":80,"cells":1243},"Roflumilast",{"EARLY_PHASE1":1244,"PHASE1":1246,"PHASE2":1248,"PHASE3":1258,"PHASE4":1260,"NA":1262},{"trials":1245,"activeCount":84},[],{"trials":1247,"activeCount":84},[],{"trials":1249,"activeCount":84},[1250],{"nctId":1251,"briefTitle":1252,"status":278,"phases":1253,"primaryCompletion":715,"completion":1254,"start":1255,"enrollment":804,"conditions":1256,"interventions":1257},"NCT01701934","Impact of Roflumilast on Visceral Adiposity and Metabolic Profile in Chronic Obstructive Pulmonary Disease",[74],"2014-12","2013-02",[24,21],[1242],{"trials":1259,"activeCount":84},[],{"trials":1261,"activeCount":84},[],{"trials":1263,"activeCount":84},[],{"intervention":1265,"totalTrials":80,"cells":1266},"Probiotic Formula",{"EARLY_PHASE1":1267,"PHASE1":1269,"PHASE2":1271,"PHASE3":1283,"PHASE4":1285,"NA":1287},{"trials":1268,"activeCount":84},[],{"trials":1270,"activeCount":84},[],{"trials":1272,"activeCount":84},[1273],{"nctId":1274,"briefTitle":1275,"status":264,"phases":1276,"primaryCompletion":1277,"completion":1277,"start":1278,"enrollment":1279,"conditions":1280,"interventions":1281},"NCT02962583","The Addition of Probiotic Consumption to a Nutritional Intervention and Caloric Restriction on Body Weight and Composition in Overweight Participants",[74],"2019-06-06","2017-01",152,[15],[1265,1282],"Placebos",{"trials":1284,"activeCount":84},[],{"trials":1286,"activeCount":84},[],{"trials":1288,"activeCount":84},[],{"intervention":1290,"totalTrials":80,"cells":1291},"Indocyanine green",{"EARLY_PHASE1":1292,"PHASE1":1294,"PHASE2":1296,"PHASE3":1311,"PHASE4":1313,"NA":1315},{"trials":1293,"activeCount":84},[],{"trials":1295,"activeCount":84},[],{"trials":1297,"activeCount":84},[1298],{"nctId":1299,"briefTitle":1300,"status":278,"phases":1301,"primaryCompletion":1302,"completion":1302,"start":1303,"enrollment":1304,"conditions":1305,"interventions":1310},"NCT05687617","Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases for Gastric Adenocarcinoma.",[74],"2024-03-27","2022-12-15",11,[1306,1307,1308,1309],"Gastric Cancer","Gastric Adenocarcinoma","Peritoneal Carcinomatosis","Peritoneal Metastases",[1290],{"trials":1312,"activeCount":84},[],{"trials":1314,"activeCount":84},[],{"trials":1316,"activeCount":84},[],{"intervention":1318,"totalTrials":80,"cells":1319},"Apabetalone",{"EARLY_PHASE1":1320,"PHASE1":1322,"PHASE2":1324,"PHASE3":1334,"PHASE4":1336,"NA":1338},{"trials":1321,"activeCount":84},[],{"trials":1323,"activeCount":84},[],{"trials":1325,"activeCount":84},[1326],{"nctId":1327,"briefTitle":1328,"status":165,"phases":1329,"primaryCompletion":1330,"completion":1330,"start":1331,"enrollment":466,"conditions":1332,"interventions":1333},"NCT04915300","Apabetalone for Pulmonary Arterial Hypertension",[74],"2025-03","2023-10",[1171],[1318],{"trials":1335,"activeCount":84},[],{"trials":1337,"activeCount":84},[],{"trials":1339,"activeCount":84},[],{"intervention":1341,"totalTrials":80,"cells":1342},"Warfarin",{"EARLY_PHASE1":1343,"PHASE1":1345,"PHASE2":1347,"PHASE3":1364,"PHASE4":1366,"NA":1368},{"trials":1344,"activeCount":84},[],{"trials":1346,"activeCount":84},[],{"trials":1348,"activeCount":84},[1349],{"nctId":1350,"briefTitle":1351,"status":1352,"phases":1353,"primaryCompletion":1354,"completion":1355,"start":1356,"enrollment":84,"conditions":1357,"interventions":1359},"NCT04002011","DOAC Versus VKA After Cardiac Surgery","WITHDRAWN",[74],"2023-01-01","2023-03-09","2022-03-09",[1358],"Anticoagulant-induced Bleeding",[1341,1360,1361,1362,1363],"Dabigatran","Rivaroxaban","Apixaban","Edoxaban",{"trials":1365,"activeCount":84},[],{"trials":1367,"activeCount":84},[],{"trials":1369,"activeCount":84},[],{"intervention":1360,"totalTrials":80,"cells":1371},{"EARLY_PHASE1":1372,"PHASE1":1374,"PHASE2":1376,"PHASE3":1382,"PHASE4":1384,"NA":1386},{"trials":1373,"activeCount":84},[],{"trials":1375,"activeCount":84},[],{"trials":1377,"activeCount":84},[1378],{"nctId":1350,"briefTitle":1351,"status":1352,"phases":1379,"primaryCompletion":1354,"completion":1355,"start":1356,"enrollment":84,"conditions":1380,"interventions":1381},[74],[1358],[1341,1360,1361,1362,1363],{"trials":1383,"activeCount":84},[],{"trials":1385,"activeCount":84},[],{"trials":1387,"activeCount":84},[],{"intervention":1361,"totalTrials":80,"cells":1389},{"EARLY_PHASE1":1390,"PHASE1":1392,"PHASE2":1394,"PHASE3":1400,"PHASE4":1402,"NA":1404},{"trials":1391,"activeCount":84},[],{"trials":1393,"activeCount":84},[],{"trials":1395,"activeCount":84},[1396],{"nctId":1350,"briefTitle":1351,"status":1352,"phases":1397,"primaryCompletion":1354,"completion":1355,"start":1356,"enrollment":84,"conditions":1398,"interventions":1399},[74],[1358],[1341,1360,1361,1362,1363],{"trials":1401,"activeCount":84},[],{"trials":1403,"activeCount":84},[],{"trials":1405,"activeCount":84},[],{"intervention":1362,"totalTrials":80,"cells":1407},{"EARLY_PHASE1":1408,"PHASE1":1410,"PHASE2":1412,"PHASE3":1418,"PHASE4":1420,"NA":1422},{"trials":1409,"activeCount":84},[],{"trials":1411,"activeCount":84},[],{"trials":1413,"activeCount":84},[1414],{"nctId":1350,"briefTitle":1351,"status":1352,"phases":1415,"primaryCompletion":1354,"completion":1355,"start":1356,"enrollment":84,"conditions":1416,"interventions":1417},[74],[1358],[1341,1360,1361,1362,1363],{"trials":1419,"activeCount":84},[],{"trials":1421,"activeCount":84},[],{"trials":1423,"activeCount":84},[],{"intervention":1363,"totalTrials":80,"cells":1425},{"EARLY_PHASE1":1426,"PHASE1":1428,"PHASE2":1430,"PHASE3":1436,"PHASE4":1438,"NA":1440},{"trials":1427,"activeCount":84},[],{"trials":1429,"activeCount":84},[],{"trials":1431,"activeCount":84},[1432],{"nctId":1350,"briefTitle":1351,"status":1352,"phases":1433,"primaryCompletion":1354,"completion":1355,"start":1356,"enrollment":84,"conditions":1434,"interventions":1435},[74],[1358],[1341,1360,1361,1362,1363],{"trials":1437,"activeCount":84},[],{"trials":1439,"activeCount":84},[],{"trials":1441,"activeCount":84},[],{"intervention":1282,"totalTrials":150,"cells":1443},{"EARLY_PHASE1":1444,"PHASE1":1446,"PHASE2":1448,"PHASE3":1454,"PHASE4":1456,"NA":1458},{"trials":1445,"activeCount":84},[],{"trials":1447,"activeCount":84},[],{"trials":1449,"activeCount":84},[1450],{"nctId":1274,"briefTitle":1275,"status":264,"phases":1451,"primaryCompletion":1277,"completion":1277,"start":1278,"enrollment":1279,"conditions":1452,"interventions":1453},[74],[15],[1265,1282],{"trials":1455,"activeCount":84},[],{"trials":1457,"activeCount":84},[],{"trials":1459,"activeCount":84},[1460],{"nctId":1461,"briefTitle":1462,"status":165,"phases":1463,"primaryCompletion":1464,"completion":1464,"start":1465,"enrollment":1466,"conditions":1467,"interventions":1468},"NCT03071731","Glittre ADL-test: Responsiveness to Acute Bronchodilation in Chronic Obstructive Pulmonary Disease (COPD)",[77],"2019-06-15","2017-04-13",34,[24],[1469,1282],"Bronchodilators",{"intervention":1471,"totalTrials":150,"cells":1472},"Combination ipratropium\u002Fsalbutamol or placebo",{"EARLY_PHASE1":1473,"PHASE1":1475,"PHASE2":1477,"PHASE3":1479,"PHASE4":1481,"NA":1483},{"trials":1474,"activeCount":84},[],{"trials":1476,"activeCount":84},[],{"trials":1478,"activeCount":84},[],{"trials":1480,"activeCount":84},[],{"trials":1482,"activeCount":84},[],{"trials":1484,"activeCount":84},[1485,1497],{"nctId":1486,"briefTitle":1487,"status":165,"phases":1488,"primaryCompletion":1489,"completion":1489,"start":1490,"enrollment":1491,"conditions":1492,"interventions":1496},"NCT01655199","Sensitivity of the Step Test to Detect Improvement in Dyspnea Following Bronchodilation in Patients With Chronic Obstructive Pulmonary Disease",[77],"2014-07","2012-09",40,[1493,1494,1495],"Moderate Chronic Obstructive Pulmonary Disease","Severe Chronic Obstructive Pulmonary Disease","Dyspnea",[1471],{"nctId":1498,"briefTitle":1499,"status":264,"phases":1500,"completion":1501,"start":1502,"enrollment":1503,"conditions":1504,"interventions":1508},"NCT01360788","GOLD Stage I Chronic Obstructive Pulmonary Disease (COPD)",[],"2011-02","2009-02",53,[1505,1506,1507],"Mild Chronic Obstructive Pulmonary Disease","Respiratory Symptoms","Physical Activity",[1471],{"intervention":1469,"totalTrials":80,"cells":1510},{"EARLY_PHASE1":1511,"PHASE1":1513,"PHASE2":1515,"PHASE3":1517,"PHASE4":1519,"NA":1521},{"trials":1512,"activeCount":84},[],{"trials":1514,"activeCount":84},[],{"trials":1516,"activeCount":84},[],{"trials":1518,"activeCount":84},[],{"trials":1520,"activeCount":84},[],{"trials":1522,"activeCount":84},[1523],{"nctId":1461,"briefTitle":1462,"status":165,"phases":1524,"primaryCompletion":1464,"completion":1464,"start":1465,"enrollment":1466,"conditions":1525,"interventions":1526},[77],[24],[1469,1282],{"intervention":1528,"totalTrials":80,"cells":1529},"Fentanyl",{"EARLY_PHASE1":1530,"PHASE1":1532,"PHASE2":1534,"PHASE3":1536,"PHASE4":1538,"NA":1540},{"trials":1531,"activeCount":84},[],{"trials":1533,"activeCount":84},[],{"trials":1535,"activeCount":84},[],{"trials":1537,"activeCount":84},[],{"trials":1539,"activeCount":84},[],{"trials":1541,"activeCount":84},[1542],{"nctId":1543,"briefTitle":1544,"status":264,"phases":1545,"primaryCompletion":1546,"completion":1546,"start":1547,"enrollment":30,"conditions":1548,"interventions":1549},"NCT01522729","Impact of Muscle Afferent Feedback During Exercise in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[77],"2012-01","2010-10",[24],[1528],{"intervention":1551,"totalTrials":80,"cells":1552},"ipratropium bromide",{"EARLY_PHASE1":1553,"PHASE1":1555,"PHASE2":1557,"PHASE3":1559,"PHASE4":1561,"NA":1563},{"trials":1554,"activeCount":84},[],{"trials":1556,"activeCount":84},[],{"trials":1558,"activeCount":84},[],{"trials":1560,"activeCount":84},[],{"trials":1562,"activeCount":84},[],{"trials":1564,"activeCount":84},[1565],{"nctId":1566,"briefTitle":1567,"status":264,"phases":1568,"primaryCompletion":1569,"completion":1570,"start":315,"enrollment":1571,"conditions":1572,"interventions":1573},"NCT00807534","Sensitivity of New Exercise Tests in Chronic Obstructive Pulmonary Disease (COPD)",[77],"2009-12","2010-06",44,[24],[1551],{"intervention":1575,"totalTrials":80,"cells":1576},"Compressed air",{"EARLY_PHASE1":1577,"PHASE1":1579,"PHASE2":1581,"PHASE3":1583,"PHASE4":1585,"NA":1587},{"trials":1578,"activeCount":84},[],{"trials":1580,"activeCount":84},[],{"trials":1582,"activeCount":84},[],{"trials":1584,"activeCount":84},[],{"trials":1586,"activeCount":84},[],{"trials":1588,"activeCount":84},[1589],{"nctId":1590,"briefTitle":1591,"status":264,"phases":1592,"primaryCompletion":491,"completion":1130,"start":1593,"enrollment":22,"conditions":1594,"interventions":1597},"NCT02150434","Evaluation of Automatic Oxygen Flow Titration During Walking in Patients With COPD",[77],"2009-11",[561,1595,1596],"Exercise","Endurance Shuttle Walking Test (Exercise at 85% of Maximal Shuttle Walking Test)",[1575,1598],"Oxygen constant flow",{"intervention":1598,"totalTrials":80,"cells":1600},{"EARLY_PHASE1":1601,"PHASE1":1603,"PHASE2":1605,"PHASE3":1607,"PHASE4":1609,"NA":1611},{"trials":1602,"activeCount":84},[],{"trials":1604,"activeCount":84},[],{"trials":1606,"activeCount":84},[],{"trials":1608,"activeCount":84},[],{"trials":1610,"activeCount":84},[],{"trials":1612,"activeCount":84},[1613],{"nctId":1590,"briefTitle":1591,"status":264,"phases":1614,"primaryCompletion":491,"completion":1130,"start":1593,"enrollment":22,"conditions":1615,"interventions":1616},[77],[561,1595,1596],[1575,1598],{"intervention":1618,"totalTrials":80,"cells":1619},"Hypnotics",{"EARLY_PHASE1":1620,"PHASE1":1622,"PHASE2":1624,"PHASE3":1626,"PHASE4":1628,"NA":1630},{"trials":1621,"activeCount":84},[],{"trials":1623,"activeCount":84},[],{"trials":1625,"activeCount":84},[],{"trials":1627,"activeCount":84},[],{"trials":1629,"activeCount":84},[],{"trials":1631,"activeCount":84},[1632],{"nctId":1633,"briefTitle":1634,"status":165,"phases":1635,"primaryCompletion":1636,"completion":1636,"start":1637,"enrollment":1638,"conditions":1639,"interventions":1640},"NCT03633305","Optimization of Insomnia Treatment in Primary Care",[77],"2023-12","2018-09-01",300,[204],[1618],{"intervention":1642,"totalTrials":80,"cells":1643},"Fasting blood sample",{"EARLY_PHASE1":1644,"PHASE1":1646,"PHASE2":1648,"PHASE3":1650,"PHASE4":1652,"NA":1654},{"trials":1645,"activeCount":84},[],{"trials":1647,"activeCount":84},[],{"trials":1649,"activeCount":84},[],{"trials":1651,"activeCount":84},[],{"trials":1653,"activeCount":84},[],{"trials":1655,"activeCount":84},[1656],{"nctId":1657,"briefTitle":1658,"status":165,"phases":1659,"primaryCompletion":1660,"completion":1660,"start":416,"enrollment":1661,"conditions":1662,"interventions":1664},"NCT01679431","Metabolic Determinants of the Progression of Aortic Stenosis",[],"2024-01",250,[1663],"Aortic Valve Stenosis",[1642],{"intervention":1666,"totalTrials":80,"cells":1667},"Aspirin",{"EARLY_PHASE1":1668,"PHASE1":1670,"PHASE2":1672,"PHASE3":1674,"PHASE4":1676,"NA":1678},{"trials":1669,"activeCount":84},[],{"trials":1671,"activeCount":84},[],{"trials":1673,"activeCount":84},[],{"trials":1675,"activeCount":84},[],{"trials":1677,"activeCount":84},[],{"trials":1679,"activeCount":84},[1680],{"nctId":1681,"briefTitle":1682,"status":264,"phases":1683,"primaryCompletion":1684,"completion":1684,"start":1685,"enrollment":1686,"conditions":1687,"interventions":1689},"NCT07066176","Establishing and Validating a Meal-provoked Intestinal Permeability Test for Nutritional and Metabolic Health Clinical Research.",[77],"2025-08-15","2025-07-07",10,[1688],"Intestinal Permeability",[1666],{"intervention":1691,"totalTrials":80,"cells":1692},"Medication Mometasone furoate and desloratadine",{"EARLY_PHASE1":1693,"PHASE1":1695,"PHASE2":1697,"PHASE3":1699,"PHASE4":1701,"NA":1703},{"trials":1694,"activeCount":84},[],{"trials":1696,"activeCount":84},[],{"trials":1698,"activeCount":84},[],{"trials":1700,"activeCount":84},[],{"trials":1702,"activeCount":84},[],{"trials":1704,"activeCount":84},[1705],{"nctId":1706,"briefTitle":1707,"status":1708,"phases":1709,"primaryCompletion":780,"completion":1710,"start":1711,"enrollment":559,"conditions":1712,"interventions":1714},"NCT00967967","Validation of the Rhinitis Control Scoring System (RCSS)","SUSPENDED",[77],"2014-09","2009-03",[18,1713],"Rhinitis",[1691],{"intervention":1716,"totalTrials":80,"cells":1717},"Ventolin",{"EARLY_PHASE1":1718,"PHASE1":1720,"PHASE2":1722,"PHASE3":1724,"PHASE4":1726,"NA":1728},{"trials":1719,"activeCount":84},[],{"trials":1721,"activeCount":84},[],{"trials":1723,"activeCount":84},[],{"trials":1725,"activeCount":84},[],{"trials":1727,"activeCount":84},[],{"trials":1729,"activeCount":84},[1730],{"nctId":1731,"briefTitle":1732,"status":264,"phases":1733,"primaryCompletion":1734,"completion":1734,"start":1735,"enrollment":1736,"conditions":1737,"interventions":1738},"NCT00876135","Role of Airway Hyperresponsiveness on Performance in Elite Swimmers.",[77],"2013-05","2008-12",57,[18],[1716],{"intervention":1740,"totalTrials":80,"cells":1741},"normal saline solution",{"EARLY_PHASE1":1742,"PHASE1":1744,"PHASE2":1746,"PHASE3":1748,"PHASE4":1750,"NA":1752},{"trials":1743,"activeCount":84},[],{"trials":1745,"activeCount":84},[],{"trials":1747,"activeCount":84},[],{"trials":1749,"activeCount":84},[],{"trials":1751,"activeCount":84},[],{"trials":1753,"activeCount":84},[1754],{"nctId":1755,"briefTitle":1756,"status":1352,"phases":1757,"primaryCompletion":491,"completion":490,"start":1758,"enrollment":84,"conditions":1759,"interventions":1761},"NCT00729274","HYPERTONIC SALINE IN ACUTE VIRAL BRONCHIOLITIS: A RANDOMIZED CLINICAL TRIAL",[77],"2011-11",[1760],"Acute Viral Bronchiolitis.",[1740],{"intervention":1763,"totalTrials":80,"cells":1764},"Sildenafil",{"EARLY_PHASE1":1765,"PHASE1":1767,"PHASE2":1769,"PHASE3":1771,"PHASE4":1773,"NA":1775},{"trials":1766,"activeCount":84},[],{"trials":1768,"activeCount":84},[],{"trials":1770,"activeCount":84},[],{"trials":1772,"activeCount":84},[],{"trials":1774,"activeCount":84},[],{"trials":1776,"activeCount":84},[1777],{"nctId":1778,"briefTitle":1779,"status":264,"phases":1780,"primaryCompletion":1758,"completion":1758,"start":838,"enrollment":19,"conditions":1781,"interventions":1782},"NCT01391104","Responsiveness of Exercise Tests in Pulmonary Arterial Hypertension",[77],[1171],[1763,1783],"Sugar Pill",{"intervention":1783,"totalTrials":80,"cells":1785},{"EARLY_PHASE1":1786,"PHASE1":1788,"PHASE2":1790,"PHASE3":1792,"PHASE4":1794,"NA":1796},{"trials":1787,"activeCount":84},[],{"trials":1789,"activeCount":84},[],{"trials":1791,"activeCount":84},[],{"trials":1793,"activeCount":84},[],{"trials":1795,"activeCount":84},[],{"trials":1797,"activeCount":84},[1798],{"nctId":1778,"briefTitle":1779,"status":264,"phases":1799,"primaryCompletion":1758,"completion":1758,"start":838,"enrollment":19,"conditions":1800,"interventions":1801},[77],[1171],[1763,1783],{"intervention":1803,"totalTrials":80,"cells":1804},"Antipsychotic use",{"EARLY_PHASE1":1805,"PHASE1":1807,"PHASE2":1809,"PHASE3":1811,"PHASE4":1813,"NA":1815},{"trials":1806,"activeCount":84},[],{"trials":1808,"activeCount":84},[],{"trials":1810,"activeCount":84},[],{"trials":1812,"activeCount":84},[],{"trials":1814,"activeCount":84},[],{"trials":1816,"activeCount":84},[1817],{"nctId":1818,"briefTitle":1819,"status":264,"phases":1820,"primaryCompletion":1821,"completion":1821,"start":918,"enrollment":1822,"conditions":1823,"interventions":1826},"NCT05686772","Prospective Multicenter Cohort Study Evaluating the Incidence and Risk Factors for Problem Gambling Among Young Adults With First-episode Psychosis",[],"2023-05-01",520,[1824,1825],"Gambling Disorder","Psychotic Disorders",[1803],{"intervention":1828,"totalTrials":80,"cells":1829},"DNA collection",{"EARLY_PHASE1":1830,"PHASE1":1832,"PHASE2":1834,"PHASE3":1836,"PHASE4":1838,"NA":1840},{"trials":1831,"activeCount":84},[],{"trials":1833,"activeCount":84},[],{"trials":1835,"activeCount":84},[],{"trials":1837,"activeCount":84},[],{"trials":1839,"activeCount":84},[],{"trials":1841,"activeCount":84},[1842],{"nctId":1843,"briefTitle":1844,"status":165,"phases":1845,"primaryCompletion":1846,"completion":1846,"start":1735,"enrollment":1847,"conditions":1848,"interventions":1850},"NCT01835054","Determinants of the Progression and Outcome of Mitral Regurgitation",[],"2024-03",440,[1849],"Mitral Valve Insufficiency",[1828],{"intervention":1852,"totalTrials":80,"cells":1853},"Bisoprolol",{"EARLY_PHASE1":1854,"PHASE1":1856,"PHASE2":1858,"PHASE3":1860,"PHASE4":1862,"NA":1864},{"trials":1855,"activeCount":84},[],{"trials":1857,"activeCount":84},[],{"trials":1859,"activeCount":84},[],{"trials":1861,"activeCount":84},[],{"trials":1863,"activeCount":84},[],{"trials":1865,"activeCount":84},[1866],{"nctId":1867,"briefTitle":1868,"status":264,"phases":1869,"primaryCompletion":267,"completion":1547,"start":268,"enrollment":1870,"conditions":1871,"interventions":1872},"NCT01273298","Effects of Cardioselective β-blockers on Dynamic Hyperinflation in COPD",[77],27,[24],[1852]]